HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

Summary

HS-201 is Verteporfin-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-201 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a photosensitizing agent (verteporfin) that can be used for imaging. HS-201 can freely enter tumor cells to selectively bind Hsp90. Due to the the verteporfin, HS-201 accumulation in the malignant cells allows for specific visualization of tumors within the body and verteporfin may allow for photodynamic therapy of tumors.

Timeline

Start

2020-07-15

Primary completion

2023-01-15

Completion

2023-02-20

Outcome

Outcome not reported

Stopped (Business): “Funding exhausted”

Drugs

Indications